Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
JERSEY CITY, N.J., Sept. 20, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Blair Atkinson MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 [email protected]
